Nannini, Drew R.
Cortese, Rene
Egwom, Peter
Palaniyandi, Senthilnathan
Hildebrandt, Gerhard C.
Article History
Received: 14 February 2023
Accepted: 1 May 2023
First Online: 10 May 2023
Declarations
:
: The Ethics Review Committee at each participating institution approved the study [CitationRef removed].
: GH has served in advisory/consulting roles for Incyte, Morphosys, Alexion Pharmaceuticals, Karyopharm Therapeutics, Seattle Genetics, Jannsen Pharmaceuticals, Daiichy Sanchyo; has stocks/ownership interests in Novartis, Insys Therapeutics, Abbvie, GW Pharmaceuticals, Cardinal Health, Clovis Oncology, Cellectis, CVS Health, Celgene, Bluebird Bio, Bristol-Myers Squibb/Medarex, Crispr Therapeutics, IDEXX Laboratories, Johnson & Johnson, Pfizer, Procter & Gamble, Vertex, Bayer, Scotts-Miracle, Charlottes Web, AImmune Therapeutics Inc, Medical PPTYS TR Inc, Caretrust Reit Inc, Moderna Therapeutics; is a member of the data safety monitoring board for Papa Therapeutics LLC; and has received research funding from Takeda, Jazz Pharmaceuticals, Pharmacyclics, Incyte, AstraZeneca.